Skip to main content
SpringerLink
Log in

Safety of the Nonselective NSAID Nabumetone

Focus on Gastrointestinal Tolerability

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Although effective in the treatment of pain associated with rheumatic conditions such as osteoarthritis and rheumatoid arthritis, long-term use of NSAIDs is primarily limited by their association with upper gastrointestinal (GI) toxicity. Adverse effects range from dyspepsia and abdominal pain to ulceration and bleeding. GI damage elicited by NSAIDs arises as the result of biochemically induced topical irritant effects and by topical and systemic pharmacological suppression of gastroprotective prostaglandins. Variation in the physicochemical properties and pharmacological profiles among the individual NSAIDs translate into inter-agent differences regarding propensity to cause adverse GI effects. Nabumetone is a nonselective NSAID that offers distinct advantages over other agents in this class with regard to GI tolerability. Its non-acidic nature and prodrug formulation, together with the lack of biliary secretion of its active metabolite, 6-methoxy-2-naphthylacetic acid, are thought to contribute to the improved GI tolerability of this drug. In head-to-head trials with other NSAIDs, nabumetone has demonstrated significant benefits regarding the incidence of GI events and ore serious perforations, ulcers and bleeds (PUBs). Pooled data from eight postmarketing, randomized, controlled trials demonstrated a lower cumulative requency of PUBs with nabumetone (0.03%; 95% CI 0.0, 0.08) versus comparator NSAIDs (1.4%; 95% CI 0.5, 2.4). Large-scale database studies also indicate that risk of serious GI complications is lower with nabumetone than comparator SAIDs. Limited comparative data suggest that nabumetone offers a GI tolerability profile similar to that of cyclo-oxygenase-2 selective NSAIDs (coxibs). Although adverse cardiovascular outcomes appear to be a class effect of the coxibs, conventional NSAIDs may also have the potential for causing atherothrombotic complications. However, based on available data, nabumetone does not appear to be associated with increased cardiovascular risk. Finally, there is no particular concern about the nephrotoxic and hepatotoxic potential of nabumetone. Nonetheless, the potential for adverse drug reactions remains, and hence nabumetone, as with any NSAID, should be used at the lowest dose, which is effective for each patient, and for the shortest time necessary to control symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Fig. 2
Fig. 3
Fig. 4
Table IV

Similar content being viewed by others

References

  1. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001 Aug 9; 345(6): 433–42

    Article  PubMed  CAS  Google Scholar 

  2. Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am J Health Syst Pharm 2006 Oct 1; 63(19): 1837–51

    Article  PubMed  CAS  Google Scholar 

  3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 Jun 17; 340(24): 1888–99

    Article  PubMed  CAS  Google Scholar 

  4. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007 Mar; 23(2): 134–41

    PubMed  CAS  Google Scholar 

  5. Laine L, Smith R, Min K, et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006 Sep 1; 24(5): 751–67 501

    Article  PubMed  CAS  Google Scholar 

  6. Langman MJ. Adverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tract. Fundam Clin Pharmacol 2003 Aug; 17(4): 393–403

    Article  PubMed  CAS  Google Scholar 

  7. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004 Jul; 63(7): 759–66

    Article  PubMed  CAS  Google Scholar 

  8. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol 2006; 47 Suppl. 1: S60-6

    Google Scholar 

  9. Lister BJ, Poland M, DeLapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993 Aug 9; 95(2A): 2S–9S

    Article  PubMed  CAS  Google Scholar 

  10. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989 Apr; 86(4): 449–58

    Article  PubMed  CAS  Google Scholar 

  11. Hedner T, Samulesson O, Wahrborg P, et al. Nabumetone: therapeutic use and safety profile in the management of osteo-arthritis and rheumatoid arthritis. Drugs 2004; 64(20): 2315–43; discussion 44–5

    Article  PubMed  CAS  Google Scholar 

  12. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999 Dec 13; 107(6A): 27S–35S; discussion S-6S

    Article  PubMed  CAS  Google Scholar 

  13. Blower PR. The unique pharmacologic profile of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 13–9

    Google Scholar 

  14. Bjarnason I, Hayllar J. Early pathogenic events in NSAID-induced gastrointestinal damage. Ital J Gastroenterol 1996 Dec; 28 Suppl. 4: 19–22

    PubMed  Google Scholar 

  15. Krause MM, Brand MD, Krauss S, et al. Nonsteroidal antiin-flammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis Rheum 2003 May; 48(5): 1438–44

    Article  PubMed  CAS  Google Scholar 

  16. Mahmud T, Rafi SS, Scott DL, et al. Nonsteroidal antiinflam-matory drugs and uncoupling of mitochondrial oxidative phos-phorylation. Arthritis Rheum 1996 Dec; 39(12): 1998–2003

    Article  PubMed  CAS  Google Scholar 

  17. Somasundaram S, Rafi S, Hayllar J, et al. Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. Gut 1997 Sep; 41(3): 344–53

    Article  PubMed  CAS  Google Scholar 

  18. Kauffman Jr GL. Gastric mucus and bicarbonate secretion in relation to mucosal protection. J Clin Gastroenterol 1981; 3 Suppl. 2: 45–50

    PubMed  Google Scholar 

  19. Giraud MN, Motta C, Romero JJ, et al. Interaction of indometh-acin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs). Biochem Pharmacol 1999 Feb 1; 57(3): 247–54

    Article  PubMed  CAS  Google Scholar 

  20. Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol 2001 Mar 15; 61(6): 631–7

    Article  PubMed  CAS  Google Scholar 

  21. Lichtenberger LM, Zhou Y, Dial EJ, et al. NSAID injury to the gastrointestinal tract: Evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol 2006; 58(11): 1421–8

    Article  PubMed  Google Scholar 

  22. Treinen-Moslen M, Kanz MF. Intestinal tract injury by drugs: importance of metabolite delivery by yellow bile road. Pharmacol Ther 2006 Dec; 112(3): 649–67

    Article  PubMed  CAS  Google Scholar 

  23. Rainsford KD, Willis C. Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects 41. on prostaglandin production. Dig Dis Sci 1982 Jul; 27(7): 624–35

    Article  PubMed  CAS  Google Scholar 

  24. Whittle BJ, Hansen D, Salmon JA. Gastric ulcer formation and cyclo-oxygenase inhibition in cat antrum follows parenteral administration of aspirin but not salicylate. Eur J Pharmacol 1985 Oct 8; 116(1–2): 153–7

    Article  PubMed  CAS  Google Scholar 

  25. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988 Dec 3; 2(8623): 1277–80

  26. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 Aug 15; 123(4): 241–9

    PubMed  CAS  Google Scholar 

  27. Sigthorsson G, Tibble J, Mahmud T, et al. NSAID-induced gastrointestinal damage: The biochemical consequences of the ’ion trapping’ hypothesis. Inflammopharmacology 2000; 8(1): 31–41

    Article  CAS  Google Scholar 

  28. Davies NM. Clinical pharmacokinetics of nabumetone: the dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet 1997 Dec; 33(6): 404–16

    Article  PubMed  CAS  Google Scholar 

  29. Jeremy JY, Mikhailidis DP, Barradas MA, et al. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function. Br J Rheumatol 1990 Apr; 29(2): 116–9

    Google Scholar 

  30. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997 Jan; 112(1): 109–17

    Article  PubMed  CAS  Google Scholar 

  31. Brett MA, Buscher G, Ellrich E, et al. Lack of enterohepatic circulation of the active metabolite of nabumetone in humans. J Rheumatol 1992; 19 Suppl. 36: 81–2

    Google Scholar 

  32. Bjarnason I, Fehilly B, Smethurst P, et al. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991; 32(3): 275–7

    Article  PubMed  CAS  Google Scholar 

  33. Sigthorsson G, Tibble J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998 Oct; 43(4): 506–11

    Article  PubMed  CAS  Google Scholar 

  34. Melarange R, Gentry C, O’Connell C, et al. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin. Dig Dis Sci 1992 Dec; 37(12): 1847–52

    Article  PubMed  CAS  Google Scholar 

  35. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993 Mar 25; 268(9): 6610–4

    PubMed  CAS  Google Scholar 

  36. Young JM, Panah S, Satchawatcharaphong C, et al. Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res 1996 May; 45(5): 246–53

    Article  PubMed  CAS  Google Scholar 

  37. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994 Dec; 271(3): 1705–12

    PubMed  CAS  Google Scholar 

  38. Giuliano F, Ferraz JG, Pereira R, et al. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation. Eur J Pharmacol 2001 Aug 24; 426(1-2): 95–103

    Article  PubMed  CAS  Google Scholar 

  39. Bernhard GC. Worldwide safety experience with nabumetone. J Rheumatol Suppl 1992 Nov; 36: 48–57

    PubMed  CAS  Google Scholar 

  40. Goodman S, Howard P, Haig A, et al. An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis. J Rheumatol 2003 Apr; 30(4): 829–31

    PubMed  CAS  Google Scholar 

  41. Carle WK, Wade AG, Kill DC, et al. Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice. J Rheumatol Suppl 1992 Nov; 36: 58–62

    Google Scholar 

  42. Eversmeyer W. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993 1993; 95 Suppl. 2A: 10S–8S

    Article  PubMed  CAS  Google Scholar 

  43. Morgan GJ, Poland M, DeLapp RE. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am J Med 1993 Aug 9; 95(2A): 19S–27S

    Article  PubMed  CAS  Google Scholar 

  44. Peura DA, Goldkind L. Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. Arthritis Res Ther 2005; 7 Suppl. 4: S7-13

    Google Scholar 

  45. Laws D, Saul S, Fehilly B. A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis. Drugs 1990; 40 Suppl. 5: 29–33

    Article  PubMed  Google Scholar 

  46. Emery P, Clarke A, Williams P, et al. Nabumetone compared with naproxen in the treatment of rheumatoid arthritis: a multi-center, double blind, randomized, parallel group trial in hospital outpatients. J Rheumatol Suppl 1992 Nov; 36: 41–7

    PubMed  CAS  Google Scholar 

  47. Bellamy N, Bensen WG, Beaulieu A, et al. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. J Rheumatol 1995 May; 22(5): 915–20

    PubMed  CAS  Google Scholar 

  48. Fleischmann RM, Flint K, Constantine G, Kolecki B. A double-masked comparison of Naprelan and nabumetone in osteoarthritis of the knee. Naprelan Study Group. Clin Ther 1997 Jul–Aug; 19(4): 642–55

    Article  PubMed  CAS  Google Scholar 

  49. Krug H, Broadwell LK, Berry M, et al. Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis. Clin Ther 2000 Jan; 22(1): 40–52

    Article  PubMed  CAS  Google Scholar 

  50. Becvar R, Urbanova Z, Vlasakova V, et al. Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard. Clin Rheumatol 1999; 18(4): 273–8

    Article  PubMed  CAS  Google Scholar 

  51. Bianchi Porro G, Montrone F, Petrillo M, et al. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol 1995 Sep; 90(9): 1485–8

    PubMed  CAS  Google Scholar 

  52. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993 Nov 22; 153(22): 2565–71

    Article  PubMed  CAS  Google Scholar 

  53. Roth SH, Bennett R, Caldron P, et al. A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol 1994 Jun; 21(6): 1118–23

    PubMed  CAS  Google Scholar 

  54. Lipani JA, Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology 1995; 3: 351–61

    Article  CAS  Google Scholar 

  55. Freston JW. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med 1999 Dec 13; 107(6A): 78S–88S; discussion 89S

    Article  PubMed  CAS  Google Scholar 

  56. Huang JQ, Sridhar S, Hunt RH. Gastrointestinal safety profile of nabumetone: a meta-analysis. Am J Med 1999 Dec 13; 107(6A): 55S–61S; discussion S-55S-61S; discussion 61S-64S

    Article  PubMed  CAS  Google Scholar 

  57. Scott DL, Palmer RH. Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. Aliment Pharmacol Ther 2000 Apr; 14(4): 443–52

    Article  PubMed  CAS  Google Scholar 

  58. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997 Nov 22; 315(7119): 1333–7

    Article  PubMed  CAS  Google Scholar 

  59. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999 Apr; 56: 18–24

    PubMed  CAS  Google Scholar 

  60. Singh G, Terry R, Ramey DR, et al. Comparative GI toxicity of NSAIDs [abstract]. Arthritis Rheum 1997; 40: S1 15

    Google Scholar 

  61. Ashworth NL, Peloso PM, Muhajarine N, et al. Risk of hospital-ization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, arthrotec, diclofenac, and naproxen in a population based cohort study. J Rheumatol 2005 Nov; 32(11): 2212–7

    PubMed  CAS  Google Scholar 

  62. Morgan Jr GJ, Kaine J, DeLapp R, et al. Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. J Clin Gastroenterol 2001 Apr; 32(4): 310–4

    Article  PubMed  Google Scholar 

  63. Brixner DI. A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study. Med Interface 1994 Nov; 7(11): 145–50

    PubMed  CAS  Google Scholar 

  64. Bentkover JD, Baker AM, Kaplan H. Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. Pharmacoeconomics 1994 Apr; 5(4): 335–42

    Article  PubMed  CAS  Google Scholar 

  65. Agrawal NM, Caldwell J, Kivitz AJ, et al. Comparison of the upper gastrointestinal safety of arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 1999 Apr; 21(4): 659–74

    Article  PubMed  CAS  Google Scholar 

  66. Chan FK, Sung JJ, Ching JY, et al. Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2001 Jan; 15(1): 19–24

    Article  PubMed  CAS  Google Scholar 

  67. Ashworth NL, Peloso PM, Muhajarine N, et al. A population based historical cohort study of the mortality associated with nabumetone, arthrotec, diclofenac, and naproxen. J Rheumatol 2004 May; 31(5): 951–6

    PubMed  Google Scholar 

  68. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343(21): 1520–8

    Article  PubMed  CAS  Google Scholar 

  69. Watson DJ, Yu Q, Bolognese JA, et al. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Curr Med Res Opin 2004 Oct; 20(10): 1539–48

    Article  PubMed  CAS  Google Scholar 

  70. Kivitz AJ, Greenwald MW, Cohen SB, et al. Efficacy and safety of rofecoxib 12.5mg versus nabumetone 1,000mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc 2004 May; 52(5): 666–74

    Article  PubMed  Google Scholar 

  71. Truitt KE, Sperling RS, Ettinger Jr WH, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) 2001 Apr; 13(2): 112–21

    CAS  Google Scholar 

  72. Weaver AL, Messner RP, Storms WW, et al. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. J Clin Rheumatol 2006 Feb; 12(1): 17–25

    Article  PubMed  Google Scholar 

  73. Bannwarth B. Do selective cyclo-oxygenase-2 inhibitors have a future? Drug Saf 2005; 28(3): 183–9

    Article  PubMed  CAS  Google Scholar 

  74. Bannwarth B, Berenbaum F. Lumiracoxib in the management of osteoarthritis and acute pain. Expert Opin Pharmacother 2007 Jul; 8(10): 1551–64

    Article  PubMed  CAS  Google Scholar 

  75. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 Jun 3; 332(7553): 1302–8

    Article  PubMed  CAS  Google Scholar 

  76. Salpeter SR, Gregor P, Ormiston TM, et al. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006 Jul; 119(7): 552–9

    Article  PubMed  CAS  Google Scholar 

  77. Cheng JW. Use of non-aspirin nonsteroidal antiinflammatory drugs and the risk of cardiovascular events. Ann Pharmacother 2006 Oct; 40(10): 1785–96

    Article  PubMed  CAS  Google Scholar 

  78. Fischer LM, Schlienger RG, Matter CM, et al. Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 2005 Apr; 25(4): 503–10

    Article  PubMed  CAS  Google Scholar 

  79. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006 Jul; 27(14): 1657–63 503

    Article  PubMed  Google Scholar 

  80. Shoor SM, Cheetham C, Graham DJ, et al. Risk of myocardial infarction in users of non selective NSAIDs: a nested case control study. Annual European Congress of Rheumatology (EULAR); 2006 Jun 21–24; Amsterdam

  81. Singh G, Mithal A, Triadafilopoulos G. Both selective cox-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Annual European Congress of Rheumatology (EULAR); 2005 Jun 8–11; Vienna

  82. Perazella MA. COX-2 selective inhibitors: analysis of the renal effects. Expert Opin Drug Saf 2002; 1(1): 53–64

    Article  PubMed  CAS  Google Scholar 

  83. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005; 11(14): 1795–804

    Article  PubMed  CAS  Google Scholar 

  84. Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005 Mar; 45(3): 531–9

    Article  PubMed  CAS  Google Scholar 

  85. Bleumink GS, Feenstra J, Sturkenboom MC, et al. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003; 63(6): 525–34

    Article  PubMed  CAS  Google Scholar 

  86. Reitblat T, Zamir D, Estis L, et al. The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Hum Hypertens 2002 Jun; 16(6): 431–4

    Article  PubMed  CAS  Google Scholar 

  87. Palmer R, Weiss R, Zusman RM, et al. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003 Feb; 16(2): 135–9

    Article  PubMed  CAS  Google Scholar 

  88. Brinker A, Goldkind L, Bonnel R, et al. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 2004; 21(7): 479–84

    Article  PubMed  CAS  Google Scholar 

  89. Aithal GP, Day CP. Nonsteridal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11(13): 563–75

    Article  PubMed  Google Scholar 

  90. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005 May; 3(5): 489–98

    Article  PubMed  CAS  Google Scholar 

  91. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004 Aug 15; 20(4): 373–80

    Article  PubMed  CAS  Google Scholar 

  92. European Medicines Agency recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines [online]. Available from URL: http://www.emea.europa.eu/ [Accessed 2008 Feb 29]

  93. European Medicines Agency recommends restricted use of nimesulide-containing medicinal products [online]. Available from URL: http://www.emea.europa.eu/ [Accessed 2008 Feb29]

  94. Willkens RF. An overview of the long-term safety experience of nabumetone. Drugs 1990; 40 Suppl. 5: 34–7

    Article  PubMed  Google Scholar 

  95. Jackson RE, Mitchell FN, Brindley DA. Safety evaluation of nabumetone in United States clinical trials. Am J Med 1987 Oct 30; 83(4B): 115–20

    Article  PubMed  CAS  Google Scholar 

  96. Miwa LJ, Jones JK, Pathiyal A, et al. Value of epidemiologic studies in determining the true incidence of adverse events: the nonsteroidal anti-inflammatory drug story. Arch Intern Med 1997 Oct 13; 157(18): 2129–36

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author would like to thank Ruth Williams of Wolters Kluwer Health Medical Communications who provided medical writing services on behalf of the Meda Group. This assistance was funded by Meda Group, which markets nabumetone in several European countries. The author has no onflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Pellegrin Hospital and Division of Therapeutics, Victor Segalen University, Bordeaux, France

    Bernard Bannwarth

Authors
  1. Bernard Bannwarth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard Bannwarth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bannwarth, B. Safety of the Nonselective NSAID Nabumetone. Drug-Safety 31, 485–503 (2008). https://doi.org/10.2165/00002018-200831060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831060-00004

Keywords

Search

Navigation